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OBJECTIVE: The present study aimed to determine the clinical benefits to critically ill patients with
severe sepsis of receiving parenteral fish-oil-based lipid emulsion as adjuvant treatment.
METHODS: This was a prospective, randomized, double-blind, placebo-controlled clinical trial of 
28 patients with severe sepsis in the intensive care unit of a primary and referral teaching hospital.
RESULTS: Fourteen patients were randomly assigned to the study group and a similar number were
placed in the control group. The study group showed a significant score reduction for Acute Physiology
and Chronic Health Evaluation (APACHE) II on day 3 (p = 0.004), day 5 (p = 0.032) and day 7 (p = 0.03),
together with APACHE III (p = 0.028) and Simplified Acute Physiology Score II (p = 0.019) on day 7. The
serum procalcitonin level was significantly decreased in the study group on day 3 (p = 0.018), day 5
(p = 0.011) and day 7 (p = 0.028). However, the serum tumour necrosis factor-α level, length of intensive
care unit and hospital stay showed no significant difference when the groups were compared.
CONCLUSION: Adjuvant treatment with fish-oil-based lipid emulsion of 10% Omegaven for critically
ill patients with severe sepsis is probably safe and helpful for rapid reduction of clinical severity of the
disease. [Asian J Surg 2011;34(1):1–10]
Key Words: clinical assessment, fish oil-based lipid emulsion, severe sepsis
Introduction
Severe sepsis and septic shock are major causes of death
in intensive care medicine worldwide, and have a high
mortality rate. Proinflammatory cytokine cascades and
complex autotoxic mediators following microbial infec-
tion with sepsis can cause life-threatening organ sequelae
and death.1,2 The high mortality rate has prompted inten-
sive worldwide debate and research that has resulted 
in the development of useful scientific therapeutic 
guidelines.3
A fish-oil-based lipid emulsion (FOBLE) is a product
that is enriched with ω-3 fatty acids, which are long-chain
polyunsaturated fatty acids and include eicosapentaenoic
acid and docosahexaenoic acid. Several large studies on var-
ious patient subgroups have demonstrated that adminis-
tration of FOBLE or ω-3 fatty acids increases beneficial
outcomes. The diseases treated include cardiovascular
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diseases, autoimmune diseases, atopic dermatitis, respira-
tory distress; they are also used in patients undergoing
abdominal surgery, as well as HIV-infected patients with
antiretroviral therapy.4–9 Over the past decade, FOBLE
treatment of sepsis has been explored widely using animal
models and human subjects. It has been shown that
FOBLE administration in sepsis seems to be associated
with improvements caused by better leukocyte function-
ality and increased generation of lipid-mediators, which
seem to modulate cytokine release, and ultimately to
reduce the processes involved in inflammation.10,11 The
immunomodulating effects of FOBLE probably have 
an impact on anti-inflammatory processes, and patients
should thus have a beneficial outcome in a clinical setting.
However, such clinical effects have not been studied in
Chinese people. Therefore, we performed a prospective
study to assess the clinical outcomes when FOBLE was
used as an adjunctive treatment for Taiwanese patients
with severe sepsis in an intensive care unit (ICU).
Patients and methods
Study design and protocol
The study was performed in the 42-bed general ICU of
Landseed Hospital, a 580-bed primary and referral teaching
hospital in the northern region of Taiwan. The study design
was a prospective, randomized, double-blind, placebo-
controlled clinical trial. The protocol was approved by the
institutional review board of Landseed Hospital and reg-
istered on ClinicalTrial.gov [NCT00634075]. Between
April 2008 and March 2009, patients admitted to the ICU
with a main diagnosis of severe sepsis were enrolled in 
the study. Written informed consent was obtained from
all participants or their authorized representatives. By 
the blocks of four randomization method, the enrolled
patients were assigned to receive supplementation with
FOBLE (10% Omegaven; Fresenius-Kabi, Bad Homburg,
Germany) as the study group or placebo (0.9% normal
saline) as the control group, via a central venous catheter;
this was carried out within 24 hours of ICU admission,
with a dosage of 100 mL/day for 5 days. Each infusion was
started at mid-day or midnight and lasted for 6 hours.
The prescription procedures were performed as follows:
the apparatus was completely wrapped with opaque cloth
bandage tape, including burette, drip chamber, catheter
and adaptor, up to the patient’s central venous catheter,
to ensure that the patient, physician and medical staff
were unable to ascertain the contents of the infusor.
Under aseptic technique, 100 mL 10% Omegaven or 0.9%
normal saline was extracted using a syringe by a research
assistant and injected into the burette after priming with
approximately 20 mL 0.9% normal saline. The apparatus
was then taken to the patient’s bedside, and an infusion
pump was used to regulate the delivery rate at 17 mL/hr,
and was set to alarm when the infusor had infused 100 mL.
Finally, 20 mL of 0.9% normal saline was injected into the
burette to flush the system. The entire apparatus was dis-
posed of when each infusion was completed. The whole
process was repeated for each infusion.
A bottle of 10% Omegaven emulsion contained 
10.0 g refined fish oil, with fatty acids content as follows:
eicosapentaenoic acid, 12.5–28.2 g/L; docosahexaenoic
acid, 14.4–30.9 g/L; myristic acid, 1.0–6.0 g/L; palmitic acid,
2.5–10.0 g/L; palmitoleic acid, 3.0–9.0 g/L; stearic acid,
0.5–2.0 g/L; oleic acid, 6.0–13.0 g/L; linoleic acid, 1.0–
7.0 g/L; linolenic acid, ≤ 2.0 g/L; octadecatetraenoic, 0.5–
4.0 g/L; eicosaenoic acid, 0.5–3.0 g/L; arachidonic acid,
1.0–4.0 g/L; docosaenoic acid, 1.5 g/L; docosapentaenoic
acid, 1.5–4.5 g/L; and other fatty acids, 10.51 g/L.
A clinical diagnosis of sepsis was defined as systemic
inflammatory response syndrome with a documented infec-
tion. Systemic inflammatory response syndrome is mani-
fested by two or more of the following four variables: (1)
hyperthermia > 38.3°C or hypothermia < 36°C; (2) tachy-
cardia (> 90 beats/min); (3) tachypnoea (rate ≥ 20 breaths/
min) or hypoxia (oxygen saturation < 90% or need for oxy-
gen supplementation of ≥ 0.4 fraction of inspired oxygen
to maintain adequate saturation); and (4) leukocytosis
(white blood cell count > 12.0×109/L), leukopenia (white
blood cell count < 4 × 109/L), or immature or band forms
> 10%. Severe sepsis was defined as sepsis with the addi-
tional complication of acute organ dysfunction, hypoten-
sion, or hypoperfusion that might cause abrupt changes
in the patient’s mental status, the presence of lactic aci-
dosis, or acute oliguria (urine <0.5 mL/kg/hr). Septic shock
was defined as persistent arterial hypotension despite
adequate volume resuscitation (20–40 mL/kg).12,13
The exclusion criteria for this study included patient age
< 18 years old; pregnancy; treatment with immunosuppres-
sive drugs; treatment with hydrocortisone > 300 mg/day
at admission; infection with human immunodeficiency
virus; plasma triglyceride concentration > 400 mg/dL; cir-
rhotic liver and/or acute hepatitis; chronic renal failure
and/or end stage renal disease; acute myocardial infarction;
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recent stroke; presence of an irreversible underlying dis-
ease that is anticipated to be rapidly fatal, or an allergic
reaction against fish or egg proteins.
Data collection and laboratory methods
Baseline characteristics included demographic data, body
mass index, information on pre-existing conditions, infec-
tious diagnosis, comorbidity, causative pathogen, haemog-
raphy and other laboratory tests; these were assessed within
24 hours of admission and before the infusion began.
Blood was collected from participants before the first lipid
preparation was infused, and this was used as a baseline.
Blood was then collected on day 1, day 3, day 5 and day 7
at 2 hours after lipid infusion.
Clinical severity was calculated at baseline, and on day
1, day 3, day 5 and day 7, using the Acute Physiology and
Chronic Health Evaluation (APACHE) II score, APACHE
III score, and Simplified Acute Physiology Score (SAPS)
II.14–16 The serum concentration of tumour necrosis 
factor (TNF)-α was determined by sandwich enzyme-
linked immunosorbent assay (BioSource; Invitrogen,
Carlsbad, CA, USA), whereas that of procalcitonin was
determined by immunoluminometric assay (Brahms
Diagnostica, Berlin, Germany). These measurements were
also obtained at baseline as well as day 1, day 3, day 5 and
day 7. Patients were followed up for 28 days after the start
of infusion or until death.
Statistical analysis
Statistical analysis was carried out using SPSS version
14.0 (SPSS, Chicago, IL, USA). Results are presented as
the mean and standard deviation. The demographic, clin-
ical and laboratory data, and the various clinical scores
(APACHE II, APACHE III and SAPS II) were compared
between the groups using nonparametric statistical test-
ing. Comparison of continuous variables used the Mann–
Whitney U test, and comparison of dichotomous variables
used the χ2 or Fisher’s exact test. Score reduction within
each group on day 1, day 3, day 5 and day 7 was calculated
by subtracting the baseline value, and was measured for
both groups. The differences in the reduced scores between
the groups were further assessed using the Mann–Whitney
U test. The differences in ICU and hospital stay between
the groups were determined using the log-rank test, and 
a Kaplan–Meier curve was constructed. A difference with
the two-tailed tests of p < 0.05 was considered statistically
significant.
Results
Demographic characteristics
During the study period, a total of 28 patients were
enrolled for analysis. There were 20 men and 8 women,
and their mean age was 69.3 ± 16.2 years (range: 32–94
years). Fourteen patients were randomly assigned to the
study group and the others formed the control group. In
the control group, one patient was withdrawn on day 2
due to the appearance of acute hepatitis (glutamate
oxaloacetate transaminase, 1748 U/L, glutamic pyruvic
transaminase, 820 U/L; Figure 1).
Baseline characteristics
The demography, body mass index and associated diseases
across the groups are shown in Table 1. Four patients had
severe sepsis and 10 had septic shock in the study group;
2 patients had severe sepsis and 12 had septic shock in the
control group. In the study group, the clinical diagnosis
of the patients was pneumonia in eight cases (1 patient
additionally had an anal abscess), infectious colitis in two
cases, as well as one case each of lung abscess, urinary
tract infection (UTI), liver abscess and endocarditis. In the
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Assessed for
eligibility (n = 168)
• Excluded (n = 140)
• Not meeting inclusion
 criteria (n = 136)
• Refused to participate
 (n = 4)
Randomised
(n = 28)
Analysed (n = 14) Analysed (n = 13)
Allocated to study
group (n = 14)
Discontinued
intervention (n = 0)
Discontinued intervention
acute hepatitis (n = 1)
Allocated to control
group (n = 14)
Completely followed
up for 28 days (n = 14)
Completely followed
up for 28 days (n = 13)
Figure 1. Flow of participants through each stage of randomized
trial.
control group, there were seven cases of pneumonia, two
of empyaema, one of primary bacteraemia, and six of UTI.
Two patients had concurrent pneumonia and UTI. In the
study group, nine patients developed acute respiratory
failure (eight required invasive mechanical ventilator sup-
plementation), five had various degrees of consciousness
disturbance, and four had acute renal insufficiency. In the
control group, six had acute respiratory failure (5 required
invasive mechanical ventilator supplementation), two had
consciousness disturbance, and six had acute renal insuf-
ficiency (Table 2). Finally, seven patients in the study group
needed vasopressor infusion compared with six in the
control group. Furthermore, according to the microor-
ganism culture results, 8 of the 10 patients in the study
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Table 1. Differences in demography and associated diseases between the groups
Study group (%) Control group (%) p
Sex (male:female) 10:4 10:4 1.0
Age (yr; mean ± SD) 64.8 ± 17.4 73.8 ± 14.2 0.190
Body mass index 21.5 ± 5.2 21.4 ± 5.6 0.783
Associated diseases* 
Hypertension 5 (35.7) 6 (42.8) 1.0
Diabetes mellitus 5 (35.7) 1 (7.1) 0.165
Stroke/organic brain diseases 3 (21.4) 4 (28.6) 1.0
Asthma/chronic lung diseases 2 (14.3) 3 (21.4) 1.0
Cardiac diseases 2 (14.3) 3 (21.4) 1.0
Others† 1 (7.1) 2 (14.3) 1.0
*Each patient might have had more than one underlying disease; †benign prostate hyperplasia, and chronic hepatitis B. SD = standard deviation.
Table 2. Differences in clinical presentation, diagnosis, comorbidity and scores between the groups
Study group (%) Control group (%) p
Clinical presentation
Severe sepsis 4 (28.6) 2 (14.3) 0.648
Septic shock 10 (71.4) 12 (85.7)
Diagnosis*
Pneumonia/empyaema/lung abscess 9 (64.3) 9 (64.3) 1.0
Liver abscess/infectious colitis 3 (21.4) 0 0.222
Anal abscess 1 (7.1) 0 1.0
Endocarditis 1 (7.1) 0 1.0
Urinary tract infection 1 (7.1) 6 (42.8) 0.077
Primary bacteraemia 0 1 (7.1) 1.0
Comorbidity*
Acute respiratory failure 9 (64.3) 6 (42.8) 0.449
Consciousness disturbance 5 (35.7) 2 (14.3) 0.385
Acute renal insufficiency 4 (28.6) 6 (42.8) 0.695
Requiring vasopressor 7 (50) 6 (42.8) 1.0
Requiring mechanical ventilator 8 (57.1) 5 (35.7) 0.449
APACHE II score† 19.3 ± 7.8 16.3 ± 7.2 0.290
APACHE III score† 75.7 ± 35.9 65 ± 26.9 0.395
SAPS II† 52.9 ± 22.5 48.4 ± 15.1 0.448
Adequate antibiotics‡ 8/10 (80) 9/9 (100) 0.474
*One patient might have had more than one diagnosis and/or comorbidity; †values presented as mean ± standard deviation in each group;
‡initial antibiotics were active against the microorganisms obtained from cultures. APACHE = Acute Physiology and Chronic Health
Evaluation; SAPS = Simplified Acute Physiology Score.
group and all 9 in the control group were prescribed ini-
tially with adequate antibiotics (Table 2). The baseline
laboratory findings and causative pathogens across the
groups are shown in Tables 3 and 4. In addition, all patients
tolerated well a 5-day course of FOBLE infusion, and the
mean daily dosage of FOBLE was 0.18 ± 0.04 g/kg (range,
0.12–0.26 g/kg). All participants survived the following 
28 days.
Clinical severity assessment
Before FOBLE prescription, the mean scores for APACHE
II, APACHE III and SAPS II were 19.3 ± 7.8 (range: 7–31),
75.7 ± 35.9 (range: 25–162) and 52.9 ± 22.5 (range: 15–93)
in the study group, respectively, and 16.3 ± 7.2 (range:
6–30), 65 ± 26.9 (range: 25–117) and 48.4 ± 15.1 (range:
29–85) in the control group, respectively. The baseline
scores between the groups showed no significant difference
(Table 2). Following treatment, the clinical scores for
APACHE II, APACHE III and SAPS II showed a decline for
both groups on day 1, day 3, day 5 and day 7, but the
measures did not show a significant difference between
the groups (Figure 2). Regarding score reduction, the
APACHE II score showed a significant difference between
the study and control groups on day 3 (10.1 ± 5.9 vs.
3.9 ± 3.7; p = 0.004), day 5 (11.2 ± 6.1 vs. 6.6 ± 4.6; p = 0.032);
and day 7 (12.9 ± 6.7 vs. 7.3 ± 5.1; p = 0.03) (Figure 3A).
APACHE III score and SAPS II revealed significant dif-
ferences between the groups on day 7 (48.3 ± 28.9 vs.
28.5 ± 16.3; p = 0.028 and 29.3 ± 14.3 vs. 15.9 ± 10.8;
p = 0.019), respectively (Figures 3B and 3C).
Serum TNF-α and procalcitonin levels
The mean serum TNF-α level, on statistical comparison
between study and control groups, showed a value of
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Table 3. Comparison of the baseline laboratory data between the groups*
Study group (n = 14) Control group (n = 14) p
WBC count (cells/mm3) 16,703 ± 9,868 15,712 ± 9,458 0.613
Haemoglobin (g/dL) 11.4 ± 2.5 11.7 ± 2.7 0.945
Platelet (×103/mm3) 232 ± 113 253 ± 214 0.679
GOT (U/L) 39.9 ± 37.9 72.2 ± 98.8 0.215
GPT (U/L) 34.5 ± 28.1 30.8 ± 24.7 0.908
Blood urea nitrogen (mg/dL) 36.9 ± 24.7 36.2 ± 21.8 0.629
Creatinine (mg/dL) 1.7 ± 0.7 1.9 ± 0.8 0.382
Sodium (meq/L) 136.5 ± 9.2 134.7 ± 6.3 0.595
Potassium (meq/L) 3.9 ± 0.7 3.9 ± 0.8 0.945
Calcium (meq/L) 7.9 ± 0.9 7.5 ± 2.1 0.401
Triglyceride (mg/dL) 129 ± 9.2 117.3 ± 72.6 0.223
Cholesterol (mg/dL) 124.7 ± 42.4 123.8 ± 35 0.890
*All values presented as mean ± standard deviation in each group. WBC = white blood cell; GOT = glutamate oxaloacetate transaminase;
GPT = glutamic pyruvic transaminase.
Table 4. Causative microorganisms of sepsis across groups
Specimen Study group (No. of isolates) Control group (No. of isolates)
Blood Staphylococcus aureus (2) Escherichia coli (2)
Enterococcus (1) Aeromonas (1)
Escherichia coli (1) Alcaligenes (1)
Klebsiella pneumonia (1) Klebsiella pneumonia (1)
Salmonella (1) Staphylococcus saprophyticus (1)
Pus/abscess/sputum Klebsiella pneumonia (4) Pseudomonas aeruginosa (2)
Acinetobacter baumannii (1) Bacteroides fragilis (1)
Providencia (1) Escherichia coli (1)
Streptococcus (1) Porphyromonas (1)
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Figure 2. Comparison of (A) APACHE II, (B) APACHE III scores
and (C) SAPS II on day 1, day 3, day 5 and day 7 between groups.
All p values > 0.05. APACHE = Acute Physiology and Chronic
Health Evaluation; SAPS = Simplified Acute Physiology Score.
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Figure 3. Comparison of (A) APACHE II, (B) APACHE III scores
and (C) SAPS II (Panel C) reductions on day 1, day 3, day 5 and
day 7 between groups. *All p values were significant for APACHE
II on day 3 (p = 0.004), day 5 (p = 0.032) and day 7 (p = 0.03), and
APACHE III score (p = 0.028) and SAPS II (p = 0.019) on day 7.
APACHE = Acute Physiology and Chronic Health Evaluation;
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44.5±32.0 versus 29.4 ± 21.8 (p = 0.203) at baseline; on the
following day 1, the values were 19.6 ± 19.6 versus
16.9±17.9 (p = 0.795); on day 3, the values were 11.0 ± 17.6
versus 8.3 ± 12.6 (p = 0.802); on day 5, the values were
5.6±10.8 versus 9.6±10.1 (p = 0.335); and on day 7, the val-
ues were 3.5 ± 9.2 versus 4.2 ± 4.7 (p = 0.295) (Figure 4A).
The serum procalcitonin level between the groups at base-
line was 10.5 ± 10.4 versus 56.7 ± 79.3 (p = 0.423); on the
following day 1, the values were 7.7 ± 8.1 versus 53.2 ± 59.4
(p = 0.055); on day 3, the values were 3.2 ± 3.1 versus
17.9 ± 15.0 (p = 0.018); on day 5, the values were 1.2 ± 1.1
versus 4.6 ± 2.5 (p = 0.011); and on day 7, the values were
0.5±0.3 versus 1.7±1.5 (p = 0.028) (Figure 4B).
Length of ICU and hospital stay
The mean (with a 95% confidence interval) length of ICU
stay and hospitalization were 10.3 (6–14.5) days and 19.6
(15.9–23.4) days, respectively, in the study group, and 8.4
(5–11.8) days and 17.5 (14.3–20.6) days for the control
group; with p values of 0.573 and 0.299, respectively
(Figure 5).
Discussion
Overall, the baseline clinical features and laboratory find-
ings did not differ significantly between the groups. All
patients were treated according to the surviving sepsis
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Figure 4. Comparison of (A) tumour necrosis factor-α and (B) procalcitonin levels at baseline and day 1, day 3, day 5 and day 7
between groups.
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campaign guidelines,3 including fluid resuscitation, early
goal-directed therapy, broad-spectrum antibiotic prescrip-
tion, and blood sugar control, as well as additional adju-
vant treatment with parenteral FOBLE of 10% Omegaven
in the study group. As shown in Table 2, more patients in
the study group required vasopressor and invasive mechan-
ical ventilation, and overall, their clinical scores seemed
to be more serious than those of the control group, how-
ever, this difference did not reach statistical significance.
The diagnoses in the study group showed a relatively
higher diversity compared with the control group (Table 2).
Two of the patients in the study group were not initially
prescribed with adequate antibiotics, but the antibiotics
were adjusted accordingly when the test results became
available. The patients in each group who had no docu-
mented culture data also showed clinical improvement
after empirical antibiotic treatment. One patient, who was
withdrawn from the control group on day 2, was thought
to have acute hepatitis followed by compromised shock.
As sepsis proceeds, there are metabolic changes in
body lipids, increased production of proinflammatory
cytokines, as well as increased pathophysiological oxida-
tion of lipids. In this context, Mayer et al17 have reported
that there was a marked and rapid increase in the free
plasma eicosapentaenoic acid (average, 35 μmol/L) and
docosahexaenoic acid (average, 65 μmol/L) levels follow-
ing parenteral 10% Omegaven FOBLE administration;
this was thought to produce anti-inflammatory and
immunomodulatory effects. In addition, Heller et al7
have reported that > 0.1 g/kg/day 10% Omegaven FOBLE
resulted in clinically beneficial effects. In our study, the
prescribed dosage was 0.12–0.26 g/kg/day; this was thought
to be optimal, and sufficient to be active for pharmaco-
logical intervention. All patients tolerated well a 5-day
course of parenteral FOBLE infusion, and there were no sig-
nificant adverse effects, although one patient in the study
group did complain of a fish oil taste during infusion.
The APACHE II and APACHE III scores and SAPS II
results are the major adult severity assessment tools 
in ICUs; Afessa et al18 have shown that the area under 
the receiver-operating characteristic curve was 0.863, 0.90
and 0.88, respectively. These scores are generally applied
in mortality prediction, as well as evaluating clinical evo-
lution. As shown in Figure 2, the clinical scores within the
groups decreased in parallel with treatment, but there
were no significant differences between the groups.
However, in terms of score reduction, the study group 
was associated with a significant decrease in APACHE II
scores on day 3, day 5 and day 7, as well as APACHE III
score and SAPS II on day 7 (Figure 3). The results agree in
part with previous studies in which fish oil supplements
were associated with increased bacterial killing, mainte-
nance of blood flow in the intestines, and modified leuko-
cyte activity,19,20 some of which might have given rise to
clinical improvement among critically ill septic patients
who had received FOBLE adjuvant treatment. In this con-
text, it is important to note that reducing clinical severity
should logically lead to increased patient self-confidence
during recovery, and this might possibly avoid undesired
comorbidity due to sepsis.
Serum procalcitonin has been used as a valuable inflam-
matory marker for severe sepsis, and generally corre-
sponds well with the degree of sepsis.21,22 In this study,
the serum procalcitonin level was significantly decreased
in the study group on day 3, day 5 and day 7 (Figure 4B).
Application of FOBLE might facilitate the resolution 
of inflammation via regulation of transcription factor
nuclear factor-κB activity and an increase in the level of
ω-3 fatty-acid-derived resolvins.23 Another reported by
Pacht et al24 has shown that inflammatory mediators are
reduced in the bronchoalveolar lavage fluid from patients
with acute respiratory distress syndrome after adminis-
tration of ω-3 fatty acids. The results of the present study
suggest that 10% Omegaven exerts an anti-inflammatory
effect. Specifically, TNF-α, an early phase proinflamma-
tory cytokine, ought to be elevated in the blood when sep-
sis occurs, because serum concentration and persistence
levels are well correlated with the risk of multiple organ
failure and mortality.25 In our study group, the mean
serum TNF-α levels were higher initially, but declined
more in the following days when compared with those in
the control group. This was an important effect, although
there was no overall statistically significant difference
between the groups. These results are different from those
of Mayer et al,17,26 who have found that TNF-α levels are
significantly suppressed by FOBLE; one important differ-
ence perhaps is that we used 0.9% normal saline as a
placebo. Some studies have reported that treatment with
FOBLE is able to shorten the length of ICU and hospital
stays in surgical patients.7,8 However, in the present study,
ICU and hospital stays were not significantly different
when the study and control groups were compared
(Figure 5). Four patients were censored following 28 days
in the study group. Of these, one needed prolonged
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antibiotic therapy due to endocarditis; one unfortunately
developed hypoglycaemia with metabolic encephalopathy
on a non-ICU ward, which resulted in prolonged hospi-
talization; and two were difficult to wean off the ventila-
tor, which prolonged the stay in the ICU and extra days of
hospitalization. Two were censored in the control group,
with one needing prolonged antibiotic treatment for
complicated empyaema, and another needing prolonged
ventilator use due to chronic obstructive pulmonary 
disease with pneumonia. In addition to the clinical sever-
ity of the disease entity, it is clear that patients’ various
associated diseases, their comorbidity, and/or the dura-
tion of their course of antibiotics all significantly influ-
ence the length of stay in the ICU and the number of days
in hospital.
Due to a constellation of selective criteria for partici-
pant enrolment, the case number was limited in this study.
To avoid an extreme statistical bias, nonparametric statis-
tical testing was used to compare the various variables
between the groups. In addition, the fact that the study
was conducted in only one ICU setting means that it might
not be possible to extrapolate these results to a multicentre
trial. Furthermore, although this study was designed to
explore specifically critically ill patients with severe sepsis
treated with adjuvant parenteral FOBLE infusion, the
participants in each group were not necessarily limited in
terms of their oral or enteral feeding, except for herbs and
extra health food supplements. The ω-3 fatty acids in the
normal diet that we provide in hospital are thought to be
extremely low when compared with parenteral FOBLE
treatment. A small amount of glucose water might have
been infused to some individual patients. None of the
patients received parenteral amino acid or lipid emulsion
infusion other than 10% Omegaven, and the isonitroge-
nous energy and daily calories were not estimated for
either group in our study. Although these might be con-
sidered to be confounders, we believe that the bias was
negligible. Finally, the TNF-α and procalcitonin tests
began midway through the study; therefore, the data were
limited for some patients.
In conclusion, the present study indicates that admin-
istration of a 5-day course of parenteral FOBLE (10%
Omegaven) as an adjuvant treatment in critically ill
patients with severe sepsis is probably safe and helpful in
terms of rapidly improving clinical severity. The results
suggest that FOBLE is beneficial when clinically treating
critically ill patients with sepsis.
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